Anifrolumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Anifrolumab and local guidelines before prescribing.
Biologic (type I IFN)
Mechanism
Type I interferon receptor antibody.
Uses
Moderate to severe SLE.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Respiratory infections, herpes zoster, infusion reactions.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active infection
Monitoring
Disease activity
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Not for severe nephritis or neuropsychiatric lupus.
More from the textbook: uses, cautions and other points
- BAFF / type I IFN receptor | Belimumab / anifrolumab | SLE
Rheumatology Anatomy Physiology Pharmacology - Type I interferon receptor | Anifrolumab | SLE | Shingles , respiratory infections
Rheumatology: assessment, investigations and drugs - Moderate disease - steroid-sparing immunosuppressants - methotrexate (joints and skin), azathioprine, mycophenolate; belimumab or anifrolumab for persistent activity (NICE TAs).
Rheumatology: Connective tissue diseases - Targeted biologics - anti-CD20 (rituximab), anti-BAFF (belimumab - SLE), anti-IFN receptor (anifrolumab - SLE), IL-6, IL-17 and TNF inhibitors, complement inhibitors, JAK inhibitors (see page 6).
Clinical Immunology: Autoimmunity, autoantibodies and complement - BAFF / type I IFN receptor | Belimumab; anifrolumab | SLE (and lupus nephritis - belimumab) | Infections; depression (belimumab); zoster (anifrolumab)
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (1 mention)
- Rheumatology: Connective tissue diseases (1 mention)
- Clinical Immunology: Autoimmunity, autoantibodies and complement (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)